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Genome-wide association studies (GWASs) have been effective approaches to dissect common genetic
variability underlying complex diseases in a systematic and unbiased way. Recently, GWASs have led to
the discovery of over 20 susceptibility loci for Alzheimer’s disease (AD). Despite the evidence showing
the contribution of these loci to AD pathogenesis, their genetic architecture has not been extensively
investigated, leaving the possibility that low frequency and rare coding variants may also occur and
contribute to the risk of disease. We have used exome and genome sequencing data to analyze the single
independent and joint effect of rare and low-frequency protein coding variants in 9 AD GWAS loci with
the strongest effect sizes after APOE (BIN1, CLU, CR1, PICALM,MS4A6A, ABCA7, EPHA1, CD33, and CD2AP) in
a cohort of 332 sporadic AD cases and 676 elderly controls of British and North-American ancestry. We
identiﬁed coding variability in ABCA7 as contributing to AD risk. This locus harbors a low-frequency
coding variant (p.G215S, rs72973581, minor allele frequency ¼ 4.3%) conferring a modest but statisti-
cally signiﬁcant protection against AD (p-value ¼ 0.024, odds ratio ¼ 0.57, 95% conﬁdence interval ¼ 0.41rch Laboratories, Department
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C. Sassi et al. / Neurobiology of Aging 46 (2016) 235.e1e235.e9235.e2e0.80). Notably, our results are not driven by an enrichment of loss of function variants in ABCA7,
recently reported as main pathogenic factor underlying AD risk at this locus. In summary, our study
conﬁrms the role of ABCA7 in AD and provides new insights that should address functional studies.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction cohort. The potential protective role of this variant has beenAlzheimer’s disease (AD) is the most common cause of pro-
gressive dementia in the elderly. Aging and genetic factors play a
critical role for the disease development. Rare coding and fully
penetrant mutations in APP, PSEN1, and PSEN2 explain part of the
AD autosomal-dominant cases. On the other hand, APOE ε4 allele
and rare coding variants in TREM2 represent the main risk factors
for late-onset and apparently sporadic AD (Chartier-Harlin et al.,
1994; Guerreiro et al., 2013). In the last 5 years, genome-wide
association studies (GWASs) identiﬁed over 20 main risk loci
inﬂuencing AD susceptibility (Harold et al., 2009; Hollingworth
et al., 2011; Lambert et al., 2009, 2013; Naj et al., 2011; Seshadri
et al., 2010). Among these, 9 have been replicated by at least 2
independent GWASs and present the strongest effect sizes after
APOE (BIN1, CLU, CR1, PICALM, MS4A6A, ABCA7, EPHA1, CD33, and
CD2AP).
GWASs have been a successful strategy to identify loci associated
to a common trait, shedding light on disease pathways and for AD
these include the following: (1) immune response (CR1, MSA4A/
MSA7A, CD2AP, CD33, EPHA1, and ABCA7); (2) vesicles trafﬁcking
(PICALM and BIN1); (3) lipid metabolism (CLU and ABCA7); and (4)
amyloid beta peripheral clearance (PICALM, BIN1, CD33, and ABCA7;
http://www.alzgene.org/). Nevertheless, the functional variant(s)
within these risk loci have not yet been fully deﬁned.
GWAS arrays tag common, low penetrant, and generally non-
coding variants that likely exert a subtle regulatory effect (0.8< odds
ratio [OR] < 1.5) on a trait, affecting gene expression, CpG islands
methylation and splicing, in cis or trans (Ramasamy et al., 2014;
Visscher et al., 2012). Whereas, low frequency (1% < minor allele
frequency [MAF] < 5%) and rare variants (MAF < 1%) with a modest
penetrance remain mostly undetected either because they are not in
the array or because, even with the implementation of imputation,
the detection of variants with MAF < 2% is not sufﬁciently accurate.
As an illustrative example, APOEGWAS hit maps to an intronic region
and it is likely driven by the APOE ε4 allele, which is a common
coding haplotype (rs429358, p.C130R and rs7412, p.R176R, MAF ¼
15%) in exon 4, that is not tagged by the custom genotyping arrays
mostly used.
Recently, resequencing studies have been powerful strategies to
bridge the gap between susceptibility loci identiﬁed and actual
disease-modifying variant(s) (Beaudoin et al., 2013; Lohmueller
et al., 2013; Rivas et al., 2011; Service et al., 2014).
Therefore, we have used exome and genome sequencing data
(1) to identify rare and low-frequency coding variants in BIN1,
CLU, CR1, PICALM, MS4A6A, ABCA7, EPHA1, CD33, and CD2AP and
(2) to investigate their single independent and combined effect
on AD susceptibility. Both the single-variant and the gene-based
association tests conﬁrmed ABCA7 as susceptibility locus associ-
ated with AD. Importantly, although ABCA7 loss of function (LoF)
mutations (indels, nonsense, and splice-site mutations) have
been recently reported as main mechanism increasing AD risk at
this locus (Steinberg et al., 2015), our results are not driven by
such variants. Whereas, we report an enrichment for ABCA7
common and low-frequency coding variants with a potential
protective effect, that is mainly responsible for our gene-based
signal. Among these, ABCA7 p.G215S is the main low-frequency
missense hit in the single-variant analysis in the discoveryfurther conﬁrmed in an independent European and North-
American cohort. Our results show that ABCA7 p.G215S exerts a
mild but statistically signiﬁcant inﬂuence, lowering the risk for
AD. Thus, conﬁrming ABCA7 to be a good potential target to
address functional studies.
2. Materials and methods
The discovery cohort was composed of 332 apparently sporadic
AD cases and 676 elderly controls, neuropathologically and clini-
cally conﬁrmed, originating from the UK and North America. The
mean age at disease onset was 71.66 years (range 41e94 years) for
cases and the mean age of ascertainment was 78.15 years (range
60e102 years) for controls (Table 1). Most of the AD cases (77%)
were late onset (>65 years at onset) (LOAD).
Among the cases and controls, 42% and 51% were female,
respectively; 58% and 47% of the cases and controls carried the
APOE ε4 allele, respectively. The APOE ε4 allele was signiﬁcantly
associated to the disease status in the National Institutes of
Health (NIH) and Alzheimer’s Disease Neuroimaging Initiative
(ADNI) series (p-value ¼ 0.02 and 1.19  109, respectively). The
threshold call rate for inclusion of the subject in analysis was 95%.
On this cohort, we performed (1) gene-based analysis (SNP-set
Sequence Kernel Association Test [SKAT] and c-alpha tests) and
(2) single-variant association analysis, targeting 23.5 kilobase
pairs (Kbs) of coding sequence. Finally, we followed up, in an
independent Caucasian data set, ABCA7 p. G215S, the only nom-
inal signiﬁcant low-frequency missense variant in the single-
marker association test in our discovery set (Fig. 1).
The follow-up data set was composed of 307 late-onset appar-
ently sporadic AD cases from North America and Europe and 501
elderly Caucasian controls from North America (Coriell repositories),
Europe, Australia, and Canada (Table 1). Written informed consent
was obtained for each clinically assessed individual, and the study
was approved by the appropriate institutional review boards. All
samples had fully informed consent for retrieval and were autho-
rized for ethically approved scientiﬁc investigation (UCLH Research
Ethics Committee number 10/H0716/3, BYU IRB, Cardiff REC for
Wales 08/MRE09/38þ5, REC Reference 04/Q2404/130, National
Research Ethics Service).
2.1. Exome sequencing
DNA was extracted from blood or brain for cases and brain only
for controls using standard protocols. Library preparation for next
generation sequencing used DNA (between 1 mg and 3 mg) frag-
mented in a Covaris E210 (Covaris Inc). DNA was end-repaired by
5’phosphorylation, using the Klenow polymerase. A polyadenine
tail was added to the 3’end of the phosphorylated fragment and
ligated to Illumina adapters. After puriﬁcation using an AMPure
DNA Puriﬁcation kit (Beckman Coulter, Inc), adapter-ligated prod-
ucts were ampliﬁed. The DNA library was then hybridized to an
exome capture library (NimbleGen SeqCap EZ Exome v2.0, Roche
Nimblegen Inc or TruSeq, Illumina Inc) and precipitated using
streptavidin-coated magnetic beads (Dynal Magnetic Beads, Invi-
trogen). These exome libraries were polymerase chain reaction
ampliﬁed and then DNA hybridized to paired-end ﬂow cells using a
Table 1
Description of the different cohorts used in this study
Cohorts N Type Sequencing strategy Origin Age (y), Mean  SD (range) Male (%) APOE, E4þ (%)
Discovery set
NIH-UCL
Cases 127 Neuropath Exome sequencing Caucasian (British) 65.5 (41e94) 46.4 58
Controls 204 Neuropath Exome sequencing Caucasian (British, North American) 79.8 (61e102) 58.3 45
WashU
Cases 23 Clinical Exome sequencing Caucasian (North American) 57 (46e75) 52.17 NA
Controls 16 Clinical Exome sequencing Caucasian (North American) 79.5 (75e92) 43.7 NA
ADNI
Cases 182 Clinical Exome sequencing Caucasian (North American) 74.65 (55e90) 67 56.6
Controls 257 Clinical Exome sequencing Caucasian (North American) 74.68 (60e90) 50.1 27.6
BYU
Controls 199 Clinical Genome sequencing Caucasian (North American) 80.8 (75e94.5) 37.7 100
Follow-up genotyping set ABCA7 rs72973581
NIH-NIA
Cases 307 Clinical Sanger sequencing Caucasian (North American, British,
Dutch, Italian, Portuguese)
Average >65 y
Controls 501 Clinical Sanger sequencing Caucasian, (North American, British,
Greek, German, Polish, Australian, Canadian)
>60 y
Key: ABCA7, ATP-binding cassette subfamily A member 7; N, number; NA, not applicable; UCL, University College London; WashU, Washington University; ADNI, Alzheimer’s
Disease Neuroimaging Initiative; BYU, Brigham Young University; NIA, National Institute on Aging; NIH, National Institutes of Health; SD, standard deviation.
C. Sassi et al. / Neurobiology of Aging 46 (2016) 235.e1e235.e9 235.e3cBot (Illumina, Inc) cluster generation system. Samples were
sequenced on the Illumina HiSeq 2000 using 2  100 paired-end
reads cycles.
2.2. Whole genome sequencing
Genome sequencing was performed in 199 controls, from the
Cache County Study on Memory in Aging. All samples were
sequenced with the use of Illumina HiSeq technology.
2.3. Sanger sequencing
ABCA7 p.G215S (rs72973581) was screened in an additional
follow-up cohort composed of 307 late-onset AD cases and 501
elderly controls. Primers were designed in Primer3 (http://bioinfo.
ut.ee/primer3-0.4.0/) using the University California Santa Cruz
(UCSC) (http://genome.ucsc.edu/) reference sequences NM_019112
(ABCA7).
Puriﬁed sequences were analyzed on an ABI 3730 DNA Analyzer
(Applied Biosystems, CA, USA) and chromatograms were visualized
in Sequencher software (version 4.2 Gene Codes Corporation, MI,
USA).
2.4. Bioinformatics
Sequence alignment and variant calling were performed against
the reference human genome (UCSC hg19). Alignment was per-
formed with the use of CASAVA software, and variant calling was
performed with the use of SAMtools (Li et al., 2009) and the
Genome Analysis Toolkit (GATK) (McKenna et al., 2010). Paired-end
sequence reads (2  100 bp paired-end read cycles) were aligned
using the Burrows-Wheeler aligner (Li and Durbin, 2009). Format
conversion and indexing were performedwith Picard (www.picard.
sourceforge.net/index.shtml). GATK was used to recalibrate base
quality scores, perform local realignments around indels, and to call
and ﬁlter the variants (McKenna et al., 2010). VCFtools was used to
annotate gene information for the remaining novel variants. We
used ANNOVAR software to annotate the variants (Wang et al.,
2010). Variants were checked against established databases (1000
Genomes Project and dbSNP v.134). Calling algorithms, pipelines,
and reference panels were the same as the pooled data sets. The
protein coding effects of variants were predicted using SIFT, Poly-
phen2, and SeattleSeq Annotation (gvs.gs.washington.edu/SeattleSeqAnnotation). All variants within the coding regions of the
9 risk loci (ABCA7 [NM_019112]; CD2AP [NM_012120]; MS4A6A
[NM_152851]; CR1 [NM_000573]; BIN1 [NM_139343]; PICALM
[NM_001206946]; EPHA1 [NM_005232]; CLU [NM_001831]; and
CD33 [NM_001772]) have been collected and analyzed. Indels were
excluded from the merged data set because they were not targeted
in the ADNI subcohort (Fig. 1) (Further details are provided in the
Supplementary Materials).
2.5. Statistical analysis
In the single-variant analysis, allele frequencies were calculated
for each low frequency and rare coding variant in cases and con-
trols, and Fisher’s exact test on allelic association was performed.
To study the joint effect of the variants detected, we performed a
gene-based analysis with SKAT and c-alpha test, and we analyzed
together for each gene the whole spectrum of allelic variability
(common, low frequency, rare, coding, and noncoding).
C-alpha test and SKAT are closely related, being both nonburden
tests, analyzing and collapsing the effect of genetic variants of
different frequency (common and rare), effect (protective,
damaging, and neutral), and effect size (modest, moderate, and
strong). SKAT can be considered an expansion of the c-alpha test
because it overcomes some of its limits. Indeed, SKAT (1) can be
applied also to the study of continuous traits and (2) does not need
any permutation.
Low frequency and rare variants were deﬁned as having a 1% <
MAF < 5% and MAF <1%, respectively, either in cases or controls.
All computations, c-alpha, and SKAT tests were performed in R
(version 64 3.0.2, http://www.r-project.org/) and PLINK/SEQ.
A p-value of 0.05 was set as a nominal signiﬁcance threshold.
Based on multiple testing correction, the thresholds for single-
variant and gene-based association tests are deﬁned by p-value ¼
1.25103 (0.05/40 [total number of coding low frequency and rare
variants detected in our study]) and 5.5  103 (0.05/9 genes),
respectively. Furthermore, we excluded singletons from the single-
variant analysis because a variant observed only once is not largely
informative about the overall distribution (Neale et al., 2011).
However, we pooled the singletons together and analyzed their
collective effect in the gene-based analysis (SKAT and c-alpha test).
In addition, we report the complete list of coding variants
detected in these GWAS loci in the supplementary table
(Supplementary Table 1).
Fig. 1. Pipeline of our study design. *INDELS have been excluded from the discovery cohort because not targeted in the ADNI data set. Abbreviations: ADNI, Alzheimer’s Disease
Neuroimaging Initiative; CTRLS, controls; INDELS, in-frame insertions and deletions; SNVs, single-nucleotide variants; UTRs, untranslated regions; WES, whole exome sequencing;
WGS, whole genome sequencing.
C. Sassi et al. / Neurobiology of Aging 46 (2016) 235.e1e235.e9235.e43. Results
The discovery set consisted of a total of 332 sporadic and mainly
late-onset AD cases and 676 elderly controls of British and North-
American ancestry (Table 1).
A total of 289 single-nucleotide variants were identiﬁed. Among
these, 128 (44.3%) were nonsynonymous, 72 (24.9%) synonymous,
83 (28.7%) were untranslated region (UTR) and 6 (2%) intronic
variants. Among the missense variants, 99 (77.34%) were rare (MAF
< 1%) and 72 of these (72.72%) were singletons (a variant observed
only once either in cases or controls). Fifteen nonsynonymous
variants (11.7%) were low frequency (1% < MAF < 5%) and 16
(12.5%) were common (MAF  5%). In addition, we report 14 novel
coding variants (not reported in ExAC, released 13 January 2015, or
dbSNP 137). None of the detected low frequency and rare coding
variants clusters within common haplotypes (MAF  5%) and,
therefore, could have been missed by GWASs and chip based ﬁne-
mapping approaches (Supplementary Tables 1 and 2). We report
the presence of 2 or 3 low frequency and/or rare variants in the
studied genes in the same individual, both for cases and controls
(Supplementary Table 3a and b).Overall, the total variant frequency of the 9 GWAS loci in our
study was in line with the one reported for the European-American
cohort in the Exome Variant Server (http://evs.gs.washington.edu/
EVS/). The only exception was represented by CR1, that showed a
2.7-fold higher relative frequency of total variants, compared to the
Exome Variant Server database (Supplementary Table 4).
PICALM harbors the lowest burden of low frequency and rare
coding variants (3.27 coding variants per kb of coding sequence). By
contrast, CD33, presents the highest relative frequency of coding
variants and the lowest relative frequency of damaging variants
(9.14 and 0.91 coding and damaging variants per kb of coding
sequence, respectively), suggesting that most coding variability in
CD33 is likely nonfunctional (Supplementary Table 5).
BIN and ABCA7 display the highest relative proportion of
damaging variants (3.92 [87.3% of its coding variability] and 3.72 [60%
of its coding variability] damaging coding variants per kb of coding
sequence, respectively), thus arguing for apotential functional impact
of missense mutations at these loci (Supplementary Table 5). More-
over, ABCA7 was the only gene harboring nonsense mutations.
Most of the low frequency and rare coding variability identiﬁed
within these loci exerts generally a relatively modest effect (mean
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generally noncoding variants identiﬁed by GWASs (Supplementary
Table 1).
3.1. Single coding variant association test
The main hits of the single variants association test map mainly
to ABCA7 (Table 2). Particularly, we report ABCA7 p.G215S
(rs72973581), that was the only low-frequency (MAF ¼ 4.3%)
missense variant showing a trend toward signiﬁcance in the single-
marker association test (p-value¼ 0.02 and corrected p-value¼ 0.8)
in the discovery set and was statistically signiﬁcant after Bonferroni
correction (p-value ¼ 6  104 and corrected p-value ¼ 0.024) in
the combined data sets (discovery set and follow-up data set).
Rs72973581 [A] results in a glycine to serine amino acid change
at the position 215 of ATP-binding cassette subfamily A member 7
(ABCA7; G215S) and its frequency was 1.56-fold higher in controls
compared to cases (MAF ¼ 4.66% and 7.24% for cases and controls,
respectively), arguing for a protective effect (OR ¼ 0.6, 95% conﬁ-
dence interval [CI] ¼ 0.38e0.95). This variant was present in
homozygosity in one control. The study possessed relatively low
power to detect a signiﬁcant association between cases and con-
trols for low frequency and rare variants. Therefore, we have fol-
lowed up ABCA7 p.G215S, carrying out Sanger sequencing in an
independent data set composed of 307 Caucasian late-onset AD
cases and 501 elderly Caucasian controls (p-value ¼ 0.012; OR ¼
0.54, 95% CI 0.31e0.89). In this follow-up data set, we conﬁrmed a
higher frequency of the ABCA7 p.G215S variant in controls
compared to cases (carrier frequency ¼ 13.5% vs. 7.8% [1.7-fold] and
MAF ¼ 7% vs. 4.3% [1.6-fold], respectively).
Finally, we also report a common coding polymorphism in ABCA7
(p.R1349Q, rs3745842), that maps 1.3 kb from a reported GWAS hit,
rs3752246, but clusters within a different common haplotype block
(MAF > 5%) (Naj et al., 2011; Supplementary Table 2). Rs3745842
major allele (G) was more frequent in cases compared to controls,
although the association was nominally signiﬁcant after multiple
testing correction (p-value ¼ 1.4  103, corrected p-value ¼ 0.081)
(Supplementary Table 6).
3.2. LoF mutations in ABCA7
LoF mutations in ABCA7 have been recently reported as main
mechanism explaining the GWAS signal and the increased sus-
ceptibility to AD.
In our cohort, we detected 5 LoF mutations in ABCA7: 2 stop-
gain mutations (p.Y1579X and p.E1974X) and 3 splice-site or near
splice-site mutations (c.7-2A>G, c.7-7T>C and c.231-12C>A).
ABCA7 p.E1974X and c.231-12C>A are novel variants and, together
with p.Y1579X, are singletons, detected only in controls
(Supplementary Table 7).
Importantly, the enrichment for ABCA7 LoF mutations and novel
variants in controls did not rely on the sequencing strategy (exome
sequencing vs. genome sequencing). These variants have not been
indeed mainly detected in the 199 BYU controls that underwent
genome sequencing (Supplementary Table 8).
Moreover, 3 very rare indels have been identiﬁed in controls in
the NIH-UCL cohort (p.1402delT, p.1638delCTT, and p.1749delC-
TACTG). ABCA7 p.1749delCTACTG is a novel mutation, and ABCA7
p.1402delT was also present in one case. These indels have been
excluded from the pooled data set because they are not targeted in
the ADNI subcohort (Supplementary Table 9; Fig. 1).
Finally, 3 nonsense mutations (p.W749X, p.W903X, and
p.R1754X) and one splice-site mutation, (c.4416þ2T>G) did not pass
either the sample or variant quality control (QC) criteria and, there-
fore, have not been included in the study (Supplementary Table 10).
Table 3
Results from the c-alpha test performed
Transcript ID Position Gene N.variants Test p-value Corrected p-value
NM_019112 chr19:1040131.1065563 ABCA7 72 c-alpha 0.0006 0.0053
NM_012120 chr6:47445789.47594915 CD2AP 20 c-alpha 0.0353 0.31
NM_152851 chr11:59939123.59950523 MS4A6A 11 c-alpha 0.0548 0.49
NM_000573 chr1:207669709.207814864 CR1 72 c-alpha 0.0677 0.6
NM_139343 chr2:127805799.127864546 BIN1 27 c-alpha 0.0730 0.65
NM_001206946 chr11:85668697.85779900 PICALM 19 c-alpha 0.0742 0.66
NM_005232 chr7:143088365.143105830 EPHA1 30 c-alpha 0.1065 0.95
NM_001831 chr8:27454493.27472251 CLU 29 c-alpha 0.4444 3.99
NM_001772 chr19:51728380.51743144 CD33 13 c-alpha 0.7142 6.42
Position is in hg19/GRCh37. Corrected p-value, p-value after Bonferroni correction (p-value* 9 [number of genes considered in the single gene-based analysis]).
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In addition to single-marker analysis, we carried out gene-wide
analysis to combine the joint signal frommultiple variants (coding
variants and ﬂanking UTRs) within a gene and to provide greater
statistical power than that for single-marker tests. All the variants
(nonsynonymous, synonymous, UTRs, and singletons) located
within the studied genes and their exon-intron ﬂanking regions
were collapsed together and their combined effect was studied.
ABCA7 was the main hit both in the SKAT and c-alpha test,
nominally and statistically signiﬁcant, respectively, after multiple
testing correction (corrected p-value ¼ 0.6 and 5.3  103,
respectively) (Tables 3 and 4). Importantly, given the exclusion of
indels in the merged discovery data set, the presence of only 2
nonsense singleton mutations in ABCA7 (p.Y1579X and p.E1974X,
both detected in controls) and 4 putative splice-site mutations
(rs3752229, rs2242437, c.231e12C>A, and rs182233998, the latter
one nominally signiﬁcant in controls), our ﬁndings are not inﬂu-
enced by a burden of LoF mutations in ABCA7. Considering the very
rare frequency of these LoF variants, their detectionwith sufﬁcient
power would have required a very large sample size. By contrast,
the top signals are represented mainly by common and low-
frequency coding variants with a higher frequency in controls
compared to cases and with a modest to intermediate protective
effect (0.329 < OR < 0.755) (Supplementary Table 6).4. Discussion
We report the results of single-variant and gene-based associ-
ation tests performed in BIN1, CLU, CR1, PICALM, MS4A6A, ABCA7,
EPHA1, CD33, and CD2AP in a cohort composed of 332 apparently
sporadic and mainly late-onset AD cases and 676 elderly Caucasian
controls from North America and the UK. In the single-variant
association test, we have analyzed the effect of low frequency and
rare coding variants (MAF < 5%), aiming to identify potential
functional variant(s) underlying the GWAS hit(s). In the gene-basedTable 4
Results from the SKAT test performed
Transcript ID Position Gene
NM_019112 chr19:1040131.1065563 ABCA7
NM_005232 chr7:143088365.143105830 EPHA1
NM_139343 chr2:127805799.127864546 BIN1
NM_012120 chr6:47445789.47594915 CD2AP
NM_000573 chr1:207669709.207814864 CR1
NM_001831 chr8:27454493.27472251 CLU
NM_152851 chr11:59939123.59950523 MS4A6A
NM_001772 chr19:51728380.51743144 CD33
NM_001206946 chr11:85668697.85779900 PICALM
Position is in hg19/GRCh37. Corrected p-value, p-value after Bonferroni correction (p-vaanalysis (SKAT and c-alpha test), we collapsed the full spectrum of
variants identiﬁed in these loci to study their collective effect.
We do not report any pathogenic mutation in APP, PSEN1, and
PSEN2 in our cohort. However, one of the controls was a hetero-
zygous carrier of the protective variant APP p.A673T (MAF 7  104
in our cohort and MAF 5  104 among the European non-Finnish,
ExAC database, released 13 January, 2015) (Jonsson et al., 2012).
TREM2 p.R47H, the secondmost common risk factor for sporadic
AD, has been detected in 6 cases (1.8%) and 4 controls (0.59%) and,
likely given our small sample size, with a MAF ¼ 0.2%, was not
signiﬁcantly associated to AD (p-value ¼ 0.09).
ABCA7 was the only signiﬁcant hit in the c-alpha test and har-
bors a low-frequency coding variant (p.G215S, rs72973581), whose
minor allele confers a modest (OR ¼ 0.57, 95% CI ¼ 0.41e0.80) but
statistically signiﬁcant protection (corrected p-value ¼0.024)
against AD. Importantly, this single-nucleotide polymorphism
(SNP) was not present in several GWAS or exome SNP arrays and
does not cluster within common haplotypes identiﬁed by tagging
SNPs, whereas it has been detected through ABCA7 direct
sequencing in the present study. Therefore, rs72973581would have
stayed likely undetected using common ﬁne-mapping genotyping
arrays. In addition, it does not cluster in the risk haplotypes iden-
tiﬁed by GWAS main hits (rs3764650, rs115550680, rs3752246, and
rs4147929), suggesting an independent signal and a likely different
pathogenic mechanism of the major allele (Hollingworth et al.,
2011; Liu et al., 2014; Naj et al., 2011; Reitz et al., 2013). Impor-
tantly, the ABCA7 p.G215S signiﬁcant protective role against AD is
supported by a targeted resequencing study of ABCA7 in a Belgian
cohort, where rs72973581 (A) frequency was 1.34-fold higher in
controls compared to cases (p-value ¼ 0.055) (Cuyvers et al., 2015).
Notably, the main variant associated to LOAD in this Belgian cohort
was a low-frequency intronic variant (rs78117248) that did not pass
our QC ﬁlter. However, in line with our ﬁndings, Cuyvers et al.
report an enrichment for common and low-frequency poly-
morphism with a modest protective role in ABCA7. Importantly,
among the top 10 genetic variants identiﬁed in our study, 3
missense mutations (rs74176364, rs114782266, and rs117187003)N.variants Test p-value Corrected p-value
72 SKAT 0.0737 0.66
30 SKAT 0.2981 2.68
27 SKAT 0.4472 4.02
20 SKAT 0.4489 4.04
72 SKAT 0.5105 4.59
29 SKAT 0.5902 5.31
11 SKAT 0.9377 8.43
13 SKAT 0.9389 8.45
19 SKAT 0.9437 8.49
lue* 9 [number of genes considered in the single gene-based analysis]).
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strongly pointing toward a functional role of these amino acid
changes and suggesting a possible shared pathogenic mechanisms
underpinning neurodegenerative and neurodevelopmental dis-
eases (He et al., 2014).
Interestingly, several lines of evidence reported that a signiﬁcant
decrease in ABCA7 levels is associated to AD. At this regard,
different and likely not mutually exclusive mechanisms have been
described to inﬂuence the protein level: (1) common and generally
noncoding variants in regulatory regions; (2) alternative splicing;
(3) increased CpG island methylation (Humphries et al., 2015;
Vasquez et al., 2013). Recently, also LoF mutations in ABCA7 have
been shown to signiﬁcantly increase the susceptibility to AD in the
Islandic population (Steinberg et al., 2015). This has been replicated
in 2 different populations (Caucasian North American and Belgian)
by 2 independent studies (Cuyvers et al., 2015; Vardarajan et al.,
2015). Therefore, we report another potential mechanism,
through which low-frequency protein coding variability in ABCA7
may inﬂuence AD risk.
Notably, ABCA7 p.G215S provides critical insights into the
genetic architecture of diseases, reinforcing the view that GWAS
loci, likewise Mendelian genes, harbor low frequency and rare
protective coding variants that can counteract with a similar effect
size the damaging alleles (OR z0.6 vs. z1.1 and z0.2 vs. z5, for
GWAS loci and Mendelian genes, respectively; Asante et al., 2015;
Jonsson et al., 2012; Nejentsev et al., 2009; Rivas et al., 2011).
ABCA7 is mainly expressed in leukocytes and in myelolym-
phatic tissues (thymus, spleen, and bone marrow) andmicroglia in
the brain (http://web.stanford.edu/group/barres_lab/brain_
rnaseq.html; http://www.uniprot.org/; Kim et al., 2008). ABCA7
encodes for ABCA7, a multi-pass protein, present on the cell, Golgi,
and endosome membranes (http://www.uniprot.org/). In vitro
and in vivo experiments have shown ABCA7 pivotal role in
phagocytosis and a likely modest role in high-density lipoprotein
biogenesis. In Abca7/ mice, macrophages and microglia display
impaired phagocytosis and clearance of amyloid from the brain,
which leads to cognitive impairment (Iwamoto et al., 2006;
Tanaka et al., 2011).
Therefore, ABCA7, likewise TREM2 and CD33, may play an
important role in regulating microglial uptake and clearance of
amyloid-beta debris.
ABCA7 p.G215S clusters within the extracellular topological
domain of ABCA7. Remarkably, at the homologous residue, the
serine is the reference amino acid in ABCA7 in different mammals
and in the homologous protein ABCA1 in humans. Thus, suggesting
that this amino acid may confer some biologic advantage and may
have been positively selected during the evolution (Supplementary
Figs. 1 and 2).
Likewise other low-frequency and rare protective variants at the
GWAS loci (Supplementary Table 11), ABCA7 p.G215 is a relatively
conserved residue among different species (Supplementary Fig. 1)
and this amino acid change (glycine to serine) may only slightly
modify the protein activity (5.86, 56, Gerd and Grantham score,
respectively). Moreover, it has been reported as a tolerated change
and benign, arguing against any possible LoF or signiﬁcant
impairment of ABCA7, that has been indeed associated to increased
risk for AD (Steinberg et al., 2015). The biological effect of this
substitution may therefore lead to a mild ABCA7 gain of function,
possibly strengthening the interaction with a binding protein or
regulating its expression. Although ABCA7 p.G215 has not been
predicted to be a coding target for miRNA (https://www.umm.uni-
heidelberg.de), a possible posttranscriptional or posttranslational
regulation should not be excluded. Importantly, the substitution of
a glycinewith a serinemay imply an additional substrate for serine-
kinases or proteases. Moreover, in a similar way, ABCA1, whose LoFvariants have been associated to AD (Kim et al., 2012; Nordestgaard
et al., 2015), has been reported to be particularly enriched for low
frequency and rare coding variants with an average 1.5-fold higher
frequency in controls compared to LOAD cases and a modest pro-
tective effect in a Greek cohort (OR¼ 0.96e0.38; Lupton et al., 2014;
Supplementary Table 12).
Thus, understanding the effect of ABCA7 p.G215S has the po-
tential of unraveling new pathogenic mechanisms underpinning
AD and may provide a promising therapeutic target that would not
signiﬁcantly alter ABCA7 overall physiological function, which is
critical for AD development.
Finally, we support the resequencing study of the GWAS loci by
Vardarajan et al. (2015), conﬁrming a burden of damaging variants
in ABCA7 and BIN1 (Supplementary Table 5) and to a lesser extent in
CD2AP, EPHA1, and MS4A6A (main hits in the gene-based analysis;
Tables 3 and 4), highlighting their potential role as susceptibility
loci for LOAD.
However, we could not replicate the main hits detected by
Vardarajan et al. in the single-variant analysis, either because
such variants have been targeted but not detected in our cohort
(ABCA7 p.E1679X, EPHA1 p.P460L, and BIN1 p.K358R) or because
the variants have been targeted but eliminated by the QC ﬁlter
(CD2AP p.K633R). Thus, suggesting a possible lack of replication
compared to the previous studies attributable to the different
population but also different sequencing strategies, capture, and
coverage. Nevertheless, EPHA1 and CD2AP harbor 2 of the main
hits detected in the single-variant analysis in our cohort
(rs11768549 and rs143297472, respectively) (Table 2), with
rs11768549 already associated with the rapid progression of the
disease in a cohort of Caucasian North American LOAD cases
(Wang et al., 2015).
In summary, we support previous studies, suggesting that (1)
ABCA7 signiﬁcantly inﬂuences AD risk; (2) ABCA7 p.G215S is likely
to reduce the susceptibility to AD; (3) GWAS hits are pleomorphic
loci harboring a complex spectrum of variants synergistically
contributing to the disease phenotype with different mechanisms,
effects (damaging, protective, and neutral), and effect sizes (0 <
OR < 4); and (4) gene-based approaches are effective methods to
mine genetic data and to accurately ﬁlter potential candidate
genes.
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